Biomarin Pharmaceutical (BMRN) Intangibles (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Intangibles came in at $204.7 million in Q1 2026, down 17.26% YoY from $247.3 million in Q1 2025, and down 4.29% on a QoQ basis from $213.8 million in Q4 2025.
Biomarin Pharmaceutical (BMRN) Intangibles (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Intangibles data on file, last reported at $204.7 million in Q1 2026.
- Quarterly Intangibles fell 17.26% year-over-year to $204.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $204.7 million (down 17.26% YoY) and the FY2025 annual result came in at $213.8 million, down 16.23% from the prior year.
- Intangibles slipped to $204.7 million in Q1 2026, from $213.8 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $374.3 million in Q1 2022 to a low of $204.7 million in Q1 2026.
- A 5-year average of $286.5 million and a median of $279.7 million in 2024 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2022 — Intangibles decreased 6.32% — and 2026, when it dropped 17.26%.
- Tracing BMRN's Intangibles over 5 years: stood at $338.6 million in 2022, then slipped by 12.96% to $294.7 million in 2023, then slipped by 13.38% to $255.3 million in 2024, then dropped by 16.23% to $213.8 million in 2025, then decreased by 4.29% to $204.7 million in 2026.
- The last three Intangibles figures came in at $204.7 million (Q1 2026), $213.8 million (Q4 2025), and $233.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 4.88 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.88 Bn |
| Mar 31, 2026 | 204.66 Mn |
| Dec 31, 2025 | 213.84 Mn |
| Sep 30, 2025 | 233.11 Mn |
| Jun 30, 2025 | 239.62 Mn |
| Mar 31, 2025 | 247.35 Mn |
| Dec 31, 2024 | 255.28 Mn |
| Sep 30, 2024 | 260.92 Mn |
| Jun 30, 2024 | 265.53 Mn |
| Mar 31, 2024 | 279.65 Mn |
| Dec 31, 2023 | 294.70 Mn |
| Sep 30, 2023 | 302.48 Mn |
| Jun 30, 2023 | 310.34 Mn |
| Mar 31, 2023 | 325.99 Mn |
| Dec 31, 2022 | 338.57 Mn |
| Sep 30, 2022 | 354.02 Mn |
| Jun 30, 2022 | 369.37 Mn |
| Mar 31, 2022 | 374.25 Mn |
| Dec 31, 2021 | 388.65 Mn |
| Sep 30, 2021 | 388.49 Mn |